目的 探討帕利哌酮緩釋片治療精神分裂癥患者的血藥濃度與臨床療效的相關(guān)性。方法 選擇2014年9月—2017年8月在新鄉(xiāng)醫(yī)學(xué)院第二附屬醫(yī)院診治的101例精神分裂癥患者，給予帕利哌酮緩釋片治療，在治療第2、4、8周進(jìn)行帕利哌酮血藥濃度檢測，同時進(jìn)行臨床療效、不良反應(yīng)的判定與記錄。結(jié)果 101例患者的帕利哌酮緩釋片平均口服劑量為（6.30±0.98）mg/d，平均血藥濃度為（31.90±14.29）ng/mL，治療第2、4、8周的服藥劑量與血藥濃度對比無顯著差異。治療第2、4、8周的有效率分別為82.2%、92.1%、98.0%，對比差異顯著（P<0.05）。治療第2、4、8周的不良反應(yīng)發(fā)生率分別為8.9%、9.9%、10.9%，對比無顯著差異。Spearman非參數(shù)相關(guān)分析顯示帕利哌酮的血藥濃度與臨床療效有效率間無顯著相關(guān)性（r=0.154）；治療第8周，發(fā)生不良反應(yīng)的患者血藥濃度明顯高于未發(fā)生不良反應(yīng)（P<0.05）。結(jié)論 帕利哌酮緩釋片治療精神分裂癥有很好的治療效果，隨著帕利哌酮緩釋血藥濃度的增加，臨床療效無顯著增加，但是可增加不良反應(yīng)發(fā)生率，需要合理調(diào)整用藥劑量。

Objective To explore the correlation between the plasma concentration and clinical efficacy of paliperidone sustained tablet in the treatment of schizophrenic patients. Methods The study time was from September 2014 to August 2017, 101 schizophrenic patients in our hospital diagnosis and treatment were selected as the research object, All patients were given the treatment of paliperidone sustained tablet, the plasma concentration were detected after treatment of 2 weeks, 4 weeks and 8 weeks, and were to determination and record the clinical efficacy and adverse reaction. Results The average oral dose of paliperidone sustained tablet in 101 patients was (6.30 ±0.98) mg/d, and the average plasma concentration was (31.90 ±14.29) ng/mL. There were no significant difference in the dosage between 2 weeks, 4 weeks and 8 weeks after treatment. The rates of treatment for 2 weeks, 4 weeks, and 8 weeks were 82.2%, 92.1% and 98%, respectively, and compared the difference were significantly (P < 0.05). The incidence of adverse reactions for 2 weeks, 4 weeks and 8 weeks were 8.9%, 9.9% and 10.9%, respectively, and compared were not significant difference (P < 0.05). Spearman nonparametric correlation analysis showed that there was no significant correlation between the plasma concentration of paliperidone and the effective rate (r=0.154, P > 0.05). The plasma concentration of paliperidone sustained tablet in patients who had adverse reactions after 8 weeks of treatment was significantly higher than those without adverse reactions (P < 0.05). Conclusions The paliperidone sustained tablet has a good clinical efficacy in the treatment of schizophrenia. With the increase of plasma concentration of paliperidone sustained tablet, there is no significant increase in the clinical efficacy, but it can increase the incidence of adverse reactions, so we need to adjust the dosage rationally.